ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesD09.3

D09.3

Billable

Carcinoma in situ of thyroid and other endocrine glands

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D09.3 is a billable code used to indicate a diagnosis of carcinoma in situ of thyroid and other endocrine glands.

Key Diagnostic Point:

Carcinoma in situ (CIS) of the thyroid and other endocrine glands refers to a localized neoplastic condition where abnormal cells are present but have not invaded surrounding tissues. This diagnosis indicates that the cancer is confined to the site of origin, which in this case is the thyroid or other endocrine glands such as the adrenal glands or pituitary gland. The presence of carcinoma in situ is significant as it represents an early stage of cancer that has the potential to progress to invasive cancer if left untreated. Surveillance protocols typically involve regular monitoring through imaging studies and laboratory tests, including thyroid function tests and ultrasound evaluations. The risk of progression to invasive cancer varies based on factors such as the specific type of carcinoma, patient age, and overall health. Early detection and intervention are crucial in managing this condition effectively, and treatment options may include surgical excision or active surveillance depending on the individual case.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Differentiating between in situ and invasive carcinoma
  • Understanding the nuances of endocrine gland involvement
  • Variability in documentation practices across specialties
  • Need for precise staging information

Audit Risk Factors

  • Inadequate documentation of the diagnosis
  • Failure to specify the site of carcinoma in situ
  • Misclassification of in situ versus invasive cancer
  • Lack of follow-up documentation for surveillance

Specialty Focus

Medical Specialties

Endocrinology

Documentation Requirements

Detailed pathology reports, imaging studies, and treatment plans.

Common Clinical Scenarios

Diagnosis of thyroid nodules, follow-up of abnormal thyroid function tests.

Billing Considerations

Endocrinologists must ensure clear documentation of the diagnosis and any surveillance protocols.

Surgical Oncology

Documentation Requirements

Operative reports, pathology findings, and post-operative follow-up notes.

Common Clinical Scenarios

Surgical intervention for thyroid carcinoma in situ, management of post-operative complications.

Billing Considerations

Surgeons should document the extent of the disease and rationale for surgical decisions.

Coding Guidelines

Inclusion Criteria

Use D09.3 When
  • According to ICD
  • CM guidelines, D09
  • 3 should be used when the carcinoma is confirmed as in situ and has not invaded surrounding tissues
  • Documentation must clearly indicate the diagnosis and any relevant staging information

Exclusion Criteria

Do NOT use D09.3 When
No specific exclusions found.

Related ICD-10 Codes

Related CPT Codes

88305CPT Code

Pathology examination, surgical

Clinical Scenario

Used when a biopsy is performed to confirm carcinoma in situ.

Documentation Requirements

Pathology report must confirm the diagnosis of carcinoma in situ.

Specialty Considerations

Endocrinologists and pathologists must collaborate for accurate diagnosis.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of cancer registries and treatment planning. D09.3 provides a clear distinction from invasive cancers, which is crucial for patient management and research.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of cancer registries and treatment planning. D09.3 provides a clear distinction from invasive cancers, which is crucial for patient management and research.

Reimbursement & Billing Impact

reimbursement and compliance with regulatory standards.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

What is the significance of carcinoma in situ?

Carcinoma in situ indicates that cancerous cells are present but have not invaded surrounding tissues, representing an early stage of cancer that can often be treated effectively.